Memo Therapeutics AG Revenue and Competitors

Memo Therapeutics AG is an innovator in the field of antibody discovery and immune repertoire analysis. Its DROPZYLLAâ„¢ platform creates a recombinant in vitro copy of an individual's B cell / antibody repertoire, which is then banked as a library. The resulting unique, large and relevant antibody libraries represent the individual's immune repertoire and are expected to contain an unprecedented number of relevant and rare antibodies. Combined with our microfluidic high throughput single cell-based functional screening system this leads to entirely new possibilities in immune repertoire analysis and antibody discovery. The business strategy of Memo Therapeutics is the discovery of therapeutic antibody candidates and target discovery for antibody and vaccine development. DROPZYLLAâ„¢ is deployed in proprietary antibody discovery programs and is made available in collaborations e.g. for screening of CAR-T; TCR-T or bi-specific antibodies.